Relmada Therapeutics price target raised to $19 from $10 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Relmada Therapeutics (RLMD) to $19 from $10 and keeps an Outperform rating on the shares. The company reported “productive” Q4 results, marked by continued execution, the analyst tells investors in a research note. The firm says the better than expected 12-months durability data strengthens its conviction in NDV-01’s “best-in-class potential” and market opportunity.